tbuckley/cabot-search huggingface dataset:
Antigen‐Inorganic Hybrid Flowers‐Based Vaccines with Enhanced Room Temperature Stability and Effective Anticancer Immunity
Authors: Yijia Liu, Xianghui Zhu, Yan Lu, Xiaoli Wang, Chuangnian Zhang, Hongfan Sun, Guilei Ma
Journal: Advanced Healthcare Materials (2019)

Abstract Particle‐based antigen carriers as adjuvants play an important role in vaccine development. Herein, an antigen‐inorganic hybrid flower‐like particle is developed as a novel vaccine carrier. Model antigen ovalbumin (OVA)‐copper (II) sulfate hybrid vaccines (OVA‐Cu‐HVs) are mildly and facilely constructed through a biomimetic mineralization process. OVA‐Cu‐HVs facilitate cellular uptake in antigen‐presenting cells and the internalization of OVA‐Cu‐HVs involves macropinocytosis‐mediated endocytosis. OVA‐Cu‐HVs can release OVA in a pH‐responsive behavior and promote cytosolic release of antigen to enhance antigen cross‐presentation. Immunization with OVA‐Cu‐HVs promotes the maturation of dendritic cells in draining lymph nodes, induces robust antigen‐specific T lymphocyte response, and inhibits tumor growth in vivo. In addition, OVA‐Cu‐HVs are efficacious after being stored for 4 weeks at room temperature and are expected to simplify vaccine storage and lower the cost of cold storage for transportation. Looking forward, OVA‐Cu‐HVs may hold strong potential to be as an effective vaccine delivery platform, which will facilitate the application of organic–inorganic hybrid flowers in biomedical areas.
Retrospective comparative study of the efficacy and safety in docetaxel and ramucirumab combination chemotherapy with or without previous immune checkpoint inhibitor treatment
Authors: D. Harada, K. Takata, S. Mori, T. Kozuki, Y. Takechi, S. Moriki, Y. Asakura, T. Ono, N. Nogami
Journal: Annals of Oncology (2019)
Abstract 12957: Endoplasmic Reticulum Stress in Pulmonary Artery Smooth Muscle Cells Contributes to the Development of Pulmonary Hypertension Induced by Chronic Hypoxia
Authors: Masayuki Koyama, Masato Furuhashi, Shutaro Ishimura, Tomohiro Mita, Takahiro Fuseya, Kohei Ono, Marenao Tanaka, Hideaki Yoshida, Kazufumi Tsuchihashi, Tetsuji Miura
Journal: Circulation (2013)

Background: Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction, and vascular remodeling in the pulmonary vasculature, and its pathogenesis involves platelet-derived growth f...
Assessment of cardiotoxicity (CT) associated with doxorubicin (dox) in patients (pts) with advanced soft tissue sarcoma (STS) in a phase III randomized trial
Authors: R.L. Jones, A. Wagner, A. Kawai, A. Shahir, V. Soldatenkova, J. Wright, W.D. Tap
Journal: Annals of Oncology (2019)
Safety and effectiveness of aflibercept + FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses
Authors: I. Chau, M.G. Fakih, P. García-Alfonso, Z. Linke, A. Ruiz-Casado, E Polo Marques, P. Picard, M. Celanovic, T. Cartwright
Journal: Annals of Oncology (2019)
Integrated care for people with long-term mental and physical health conditions in low-income and middle-income countries: Shalini Ahuja - Joint first author
Authors: Graham John Thornicroft, Shalini Ahuja, Sarah Barber, Daniel Chisholm, Pamela Y Collins, Sumaiyah Docrat, Lara Fairall, Heidi Katharina Lempp, Unaiza Niaz, Vicky Ngo, Vikram Patel, Inge Petersen, Martin James Prince, Maya Hazel Semrau, Jurgen Unutzer, Yueqin Huang, Shuo Zhang
Journal: The Lancet Psychiatry (2018)
Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Authors: C. Rolfo, R. Dziadziuszko, R.C. Doebele, G. Demetri, B. Simmons, X. Huang, C. Ye, L. Paz-Ares
Journal: Annals of Oncology (2019)
Illness perceptions, quality of life and mood in metastatic breast cancer patients
Authors: I. Domingues, J. Carvalho, E.A. Pratas, S. Pinheiro, S. Amaral, T. Pereira, F. Pontes, R. Félix, A. Chaves, M. Mariano, T. Carvalho, P. Madeira, A. Pêgo, S. Broco, R. Garcia, I. Pazos, A. Pais, G. Sousa
Journal: Annals of Oncology (2019)
Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy
Authors: J.A. Marín Jiménez, A. Capasso, S.M. Bagby, S.J. Hartman, J. Shulman, J. Barkow, B.W. Yacob, P. Blatchford, T.M. Pitts, J. Lang
Journal: Annals of Oncology (2019)
Absence of HIF1A Leads to Glycogen Accumulation and an Inflammatory Response That Enables Pancreatic Tumor Growth
Authors: Marco Maruggi, Fabiana Izidro Layng, Robert Lemos, Guillermina Garcia, Brian P. James, Monica Sevilla, Ferran Soldevilla, Bas J. Baaten, Petrus R. de Jong, Mei Yee Koh, Garth Powis
Journal: Cancer Research (2019)

Abstract Cancer cells respond to hypoxia by upregulating the hypoxia-inducible factor 1α (HIF1A) transcription factor, which drives survival mechanisms that include metabolic adaptation and induction of angiogenesis by VEGF. Pancreatic tumors are poorly vascularized and severely hypoxic. To study the angiogenic role of HIF1A, and specifically probe whether tumors are able to use alternative pathways in its absence, we created a xenograft mouse tumor model of pancreatic cancer lacking HIF1A. After an initial delay of about 30 days, the HIF1A-deficient tumors grew as rapidly as the wild-type tumors and had similar vascularization. These changes were maintained in subsequent passages of tumor xenografts in vivo and in cell lines ex vivo. There were many cancer cells with a "clear-cell" phenotype in the HIF1A-deficient tumors; this was the result of accumulation of glycogen. Single-cell RNA sequencing (scRNA-seq) of the tumors identified hypoxic cancer cells with inhibited glycogen breakdown, which promoted glycogen accumulation and the secretion of inflammatory cytokines, including interleukins 1β (IL1B) and 8 (IL8). scRNA-seq of the mouse tumor stroma showed enrichment of two subsets of myeloid dendritic cells (cDC), cDC1 and cDC2, that secreted proangiogenic cytokines. These results suggest that glycogen accumulation associated with a clear-cell phenotype in hypoxic cancer cells lacking HIF1A can initiate an alternate pathway of cytokine and DC-driven angiogenesis. Inhibiting glycogen accumulation may provide a treatment for cancers with the clear-cell phenotype. Significance: These findings establish a novel mechanism by which tumors support angiogenesis in an HIF1α-independent manner.
Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC)
Authors: J. Furlanetto, V. Nekljudova, A. Schneeweiss, C. Thode, C. Denkert, M. Untch, M. Bassy, T. Karn, P.A. Fasching, E. Stickeler, C. Schem, F. Marmé, E.-M. Grischke, M. van Mackelenbergh, D. Strik, S. Schmatloch, V. Müller, S. Loibl
Journal: Annals of Oncology (2019)
The Bcl-2 Family Inhibitor ABT-263 Shows Significant but Reversible Thrombocytopenia in Mice.
Authors: Alex R. Shoemaker, Michael J. Mitten, Jessica Adickes, Anatol Oleksijew, Haichao Zhang, Joy Bauch, Kennan Marsh, David J. Frost, David Madar, Christin Tse, Stephen W. Fesik, Saul H. Rosenberg, Steven W. Elmore
Journal: Blood (2006)
Abstract 15591: A Novel Noninvasive Measure of Cerebral Autoregulation Correlates With a Standard Invasive Technique in Congenital Heart Disease Neonates: A Pilot Study
Authors: Nhu Tran, Sadaf Soleymani, Lisa Paquette, S. Ram Kumar, Paul Macey, Ashok Panigrahy, Jodie Votava-Smith
Journal: Circulation (2017)

Introduction: Children with congenital heart disease (CHD) have evidence of brain dysmaturation and injury, and may be at risk for impaired cerebral autoregulation (CA). Standard methods to assess ...
Thermal liquid biopsy as a valuable tool in lung cancer screening programs
Authors: A. Rodrigo, S. Vega, J. Ojeda Cabrera, O. Sanchez-Gracia, A. Callejo, A. Fernandez, P. Iranzo, M. Cruellas Lapena, E. Quilez Bielsa, A. Velazquez-Campoy, O. Abian, D. Isla
Journal: Annals of Oncology (2019)
Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases
Authors: F. Pietrantonio, J. Lee, L. Boussemart, C. Schinke, G. Srkalovic, R. Madison, J.S. Ross, V.A. Miller, B.M. Alexander, S.M. Ali, A.B. Schrock, G.A. Daniels
Journal: Annals of Oncology (2019)
Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Authors: J.-M. Lavoie, G. Vandekerkhove, M. Annala, S. Taavitsainen, N.L. Sundahl, S. Walz, T. Sano, D. Khalaf, T. Todenhöfer, P. Ost, C.K. Kollmannsberger, K.N. Chi, P.C. Black, A.W. Wyatt, B.J. Eigl
Journal: Annals of Oncology (2019)
Effect of a fluid bolus on cardiovascular collapse among critically ill adults undergoing tracheal intubation (PrePARE): a randomised controlled trial
Authors: David R Janz, Jonathan D Casey, Matthew W Semler, Derek W Russell, James Dargin, Derek J Vonderhaar, Kevin M Dischert, Jason R West, Susan Stempek, Joanne Wozniak, Nicholas Caputo, Brent E Heideman, Aline N Zouk, Swati Gulati, William S Stigler, Itay Bentov, Aaron M Joffe, Todd W Rice, David R Janz, Derek J Vonderhaar, Ross Hoffman, Naveen Turlapati, Sneha Samant, Page Clark, Amita Krishnan, Joseph Gresens, Cody Hill, Bobby Matthew, Jason Henry, Jason Miller, Rose Paccione, Abdulla Majid-Moosa, Jairo I Santanilla, Matthew W Semler, Todd W Rice, Jonathan D Casey, Brent E Heideman, Erin M Wilfong, Justin C Hewlett, Stephen J Halliday, V Eric Kerchberger, Ryan M Brown, Luis E Huerta, Christopher M Merrick, Thomas Atwater, Emily G Kocurek, Andrew C McKown, Nichelle I Winters, Luke E Habegger, Matthew F Mart, Jeannette Z Berg, Christina C Noblit, Lisa N Flemmons, Kevin Dischert, Aaron Joffe, Itay Bentov, Trefan Archibald, Alejandro Arenas, Camelia Baldridge, Gaurav Bansal, Christopher Barnes, Nicholas Bishop, Beth Bryce, Laura Byrne, Rachel Clement, Carla DeLaCruz, Priya Deshpande, Zi Gong, John Green, Austin Henry, Andrew Herstein, Jessica Huang, Jake Heier, Bonnie Jenson, Lynn Johnston, Cara Langeland, Calvin Lee, Alex Nowlin, Travis Reece-Nguyen, Hunter Schultz, Graeme Segal, Ian Slade, Stuart Solomon, Sarah Stehpey, Robin Thompson, David Trausch, Carson Welker, Raymond Zhang, Derek Russell, Aline Zouk, Swati Gulati, William Stigler, Jason Fain, Bryan Garcia, David Lafon, Chao He, James O'Connor, David Campbell, Jordan Powner, Samuel McElwee, Cristina Bardita, Kevin D'Souza, G Bruno Pereira, Sarah Robinson, Scott Blumhof, James Dargin, Susan Stempek, Joanne Wozniak, Piyanuch Pataramekin, Dhruv Desai, Ekaterina Yayarovich, Robert DeMatteo, Sandeep Somalaraiu, Christopher Adler, Courtney Reid, Michael Plourde, Jordan Winnicki, Timothy Noland, Tamar Geva, Lee Gazourian, Avignat Patel, Khaled Eissa, Joshua Giacotto, Daniel Fitelson, Michael Colancecco, Anthony Gray, Jason R West, Nicholas Caputo, Mary Ryan, Thomas Parry, Benjamin Azan, Ali Khairat, Renee Morton, David Lewandowski, Carlos Vaca
Journal: The Lancet Respiratory Medicine (2019)
Final results from phase II of combination with canerpaturev (formerly HF10), an oncolytic viral immunotherapy, and ipilimumab in unresectable or metastatic melanoma in second-or later line treatment
Authors: K. Yokota, T. Isei, H. Uhara, Y. Fujisawa, T. Takenouchi, Y. Kiyohara, H. Uchi, H. Saruta, H. Ihn, T. Inozume, D. Watanabe, A. Takahashi, S. Fukushima, M. Tanaka, N. Yamazaki
Journal: Annals of Oncology (2019)
Incidental early occult ovarian cancer after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers followed in a community public hospital
Authors: B Grana Suarez, A. Molina, J. Prato, C. Czestokowa, C. Conde, C Reboredo Rendo, M. Quindos, E. Perez, R Lesta Mellid, P. Cordeiro, I. Gomez-Randulfe, S. Antolin, L. Calvo
Journal: Annals of Oncology (2019)
Lung and colon cancer costs among chemotherapy patients after an FDA policy change.
Authors: Kevin Stroupe, Elizabeth Tarlov, Thomas Weichle, Qiuying Zhang, Todd Lee, Laura Christian Michaelis, Ramon Durazo-Arvizu, Howard Ozer, Denise Marie Hynes
Journal: Journal of Clinical Oncology (2013)

e14578 Background: Emerging evidence of adverse events from erythropoietin-stimulating agents (ESAs) led FDA to add a black box warning to ESA labeling in March 2007, after which ESA use declined. We examined the impact on healthcare costs for lung and colon patients receiving chemotherapy in Department of Veterans Affairs (VA) healthcare facilities. Methods: Patients were newly diagnosed with lung or colon cancer during 2002-2008, had at least 2 chemotherapy visits, and did not have kidney disease. For each patient, we defined a chemotherapy episode as the time beginning with the first chemotherapy visit and ending with the last visit before a break of 90 days with no chemotherapy. We calculated outpatient anemia management (ESA and transfusion), cancer-related, and total healthcare costs from 30 days before to 90 days after the chemotherapy episode. We compared costs between patients with chemotherapy episodes before (PRE) and after (POST) March 2007 using multivariable regression analyses controlling for patient and facility characteristics. Costs were adjusted to 2010 dollars using the consumer price index. Results: There were 16,828 study patients: 13,630 lung and 3,198 colon. POST-period ESA use was markedly lower than PRE-period use for both groups (lung, 23% vs. 39%, P&lt;0.01; colon, 11% vs. 23%, P&lt;0.01). More lung cancer patients received transfusions in the POST than the PRE period, though the increase was small (27% vs. 25%, P=0.04). Consequently, adjusted POST-period anemia treatment costs were lower (lung, $526 lower, P&lt;0.01; colon, $504 lower, P&lt;0.01). Cancer-related and total costs were nonetheless higher in the POST period, due primarily to higher outpatient costs (adjusted cancer-related costs: lung, $4,500 higher, P&lt;0.01; colon, $10,343 higher, P&lt;0.01; adjusted total costs: lung, $4,706 higher, P&lt;0.01; colon, $11,414 higher, P&lt;0.01). Conclusions: Outpatient anemia management costs were lower during the period after the FDA policy change. There was no substitution effect of transfusion in place of ESAs. These declines in anemia management costs were not enough to offset the higher cancer-related costs, resulting in higher total healthcare costs.
Clarifying the roles of patients in research
Authors: Kristin Liabo, Kate Boddy, Helen Burchmore, Emma Cockcroft, Nicky Britten
Journal: British Journal of Sports Medicine (2019)

The term ‘patient’ no longer denotes a passive recipient of healthcare. Patients have demanded, and are increasingly given, the opportunity to influence health services and policies.1 Similarly, in health research patients are sought as partners in study design and governance.2 This is reflected in The BMJ ’s patient partnership initiative (www.bmj.com/campaign/patient-partnership),3 the Patient-Centred Outcomes Research Institute (PCORI) in the US,4 and the National Institute for Health Research (NIHR) in the UK.5 

Because of the history of (un)ethical conduct in research, including patients as partners in research studies requires clarity about what the role includes. Patients’ roles must be defined so that we achieve meaningful patient partnership and well conducted, ethical research.

‘The patient’ is a construct that assumes an inherent imbalance of power and includes expectations of compliance by those inhabiting it.6 That it has taken so long to acknowledge the value patients bring to healthcare and research emphasises just how difficult it can be to broaden their role beyond passively receiving treatment.

Many …
Analysis of 105,000 cancer patients: Have they been discussed in oncologic multidisciplinary team meetings? A nationwide population-based study in the Netherlands
Authors: J.E.W. Walraven, I.M.E. Desar, K.J.J.M Hoeven van der, K.K.H. Aben, R. Van Hillegersberg, C.R.N. Rasch, V.E.P.P Lemmens, R.H.A. Verhoeven
Journal: Annals of Oncology (2019)
A multivariate model to define prognostic groups among patients with melanoma brain metastases: A 10-year retrospective cohort study
Authors: G. Pelizzari, E. Bertoli, M.G. Vitale, S. Buriolla, L. Palmero, M. Bartoletti, D. Zara, D. Basile, D. Iacono, G. Pascoletti, M. Cinausero, E. Poletto, S. Bolzonello, A. Freschi, F. Puglisi, G. Fasola, A.M. Minisini
Journal: Annals of Oncology (2019)
Molecular EGFR/PD-L1 profile of glioblastoma: Hints for therapeutic strategies
Authors: W. Szopa, P. Czekaj, K. Malarz, A. Mrozek-Wilczkiewicz, D. Plewka, M. Niedbała, M. de Mezer, G. Kramer-marek, W. Kaspera
Journal: Annals of Oncology (2019)
Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062
Authors: K. Shitara, E. Van Cutsem, Y.-J. Bang, C.S. Fuchs, L. Wyrwicz, K.W. Lee, I. Kudaba, M. Garrido, H. Cheol Chung, H.R. Castro, W. Mansoor, M I F M Braghiroli, E. Goekkurt, J. Chao, Z.A. Wainberg, U. Kher, S. Shah, S.P. Kang, J. Tabernero
Journal: Annals of Oncology (2019)
Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)
Authors: R.A. Stahel, A. Curioni, S. Rohrmann, U. Dafni, U. Sandner, N. Andratschke, G. Dimopoulou, M. Guckenberger, M. Kohler, K. Matthes, I. Opitz, W. Weder
Journal: Annals of Oncology (2019)
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer
Authors: A. J. Armstrong, S. Halabi, I. F. Tannock, d. Ronald, M. A. Eisenberger
Journal: Journal of Clinical Oncology (2008)

5074 Background: We sought to evaluate the relationship of baseline body mass index (BMI), NIH-defined presence of obesity, and serum testosterone levels with disease-specific outcomes and prognosis in men with castration resistant metastatic prostate cancer (CRPC). Methods: BMI and testosterone level were evaluated for their ability to predict overall survival (OS) and progression-free survival (PFS) in multivariable analysis using data from the TAX327 clinical trial. This was an international phase III randomized controlled trial of one of two schedules of docetaxel and prednisone compared with mitoxantrone and prednisone. BMI and testosterone were additionally examined for prognostic significance in determining PSA declines with chemotherapy as well as the relationship to other prognostic factors. Results: In this study of 1006 men with CRPC, the median serum testosterone level was 14.5 ng/dl (range 0–270), the median BMI was 27 kg/m2 (range 15.7–46.5), and 26% of men were obese or morbidly obese (BMI > 30). Obese men were significantly more likely to be younger, have fewer visceral metastases, lower PSA and alkaline phosphatase, and have higher performance status, primary Gleason sum, testosterone, and hemoglobin levels as compared to non-obese men. In multivariable analysis, neither BMI nor the presence of obesity was significantly associated with PSA declines with therapy, progression-free survival, or overall survival. Baseline testosterone in the castrate range was also not associated with disease outcome, including PSA declines, PFS, or OS. Conclusions: In this multicenter international trial of men with CRPC, neither BMI nor serum testosterone in the castrate range were associated with prostate cancer outcomes. The cut-off threshold for castrate levels of serum testosterone should remain ≤50 ng/dl. Higher levels of serum testosterone among obese men suggest incomplete gonadal suppression with current therapies, but these differences may not be clinically relevant in men with CRPC. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration sanofi-aventis sanofi-aventis sanofi-aventis
A novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer exhibited early-onset cytokine release syndrome and subsequent tumour responses in synovial sarcoma patients
Authors: H. Hattori, M. Ishihara, S. Kitano, Y. Miyahara, H. Kato, H. Mishima, N. Yamamoto, T. Funakoshi, T. Kojima, T. Sasada, E. Sato, S. Okamoto, D. Tomura, H. Chono, I. Nukaya, J. Mineno, H. Ikeda, T. Watanabe, S. Kageyama, H. Shiku
Journal: Annals of Oncology (2019)
Skindex‐29 量表哥伦比亚版的构念效度和反应性
Authors: D. Vasquez, D.‐C. Aguirre, G. Sanclemente
Journal: British Journal of Dermatology (2019)

在三十年之前,人们对疾病和治疗对患者日常生活的影响了解很少。最近,由于国际科学合作的增多,尤其是患者报告结果 (PRO) 和生活质量 (QOL) 量表已成为根据患者观点评估任何药物的疗效的重要工具。但由于大多数 QOL 量表以英语开发,使其适用于不同文化并同时确保原始工具(量表)与调整后的量表等效(该流程称作“验证”)的需求日益增长。由于 QOL 量表是一个复杂概念,其中问题的准确含义在不同国家和文化的个体间有差异,因此确立其效度非常困难。就这点而言,构念效度(工具测量构念或概念的能力)、聚合/区分效度(该工具相比其他工具的相关性/缺乏相关性)及反应性(工具检测随时间变化的能力)都是测试工具准确性的关键属性 。因此,本研究的目的在于评估 Skindex-29 量表哥伦比亚版 QOL 量表的这些属性。在 209 名皮肤科患者和 56 名无皮肤病者中进行了效度和反应性测试。患者患有炎性或非炎性皮肤病。构念效度通过验证性因子分析进行评估,其显示工具的所有问题(项目)之间的关系,及其如何围绕 QOL 概念设置。聚合/区分效度通过斯皮尔曼相关系数检验进行评估,反应性通过标准化反应均数进行测试。作者发现,Skindex-29 量表哥伦比亚版是一个有效的、临床上敏感的工具,其可用于临床实践(例如,医生治疗患者)和研究,以测量皮肤病对皮肤科患者生活质量的影响。
Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173)
Authors: R. Wesolowski, A.M. Brufsky, M. Chambers, S. Bhattacharya, M. Lustberg, J.B. VanDeusen, S. Sardesai, N. Williams, A.M. Noonan, M. Phelps, M. Grever, J. Stephens, W. Carson, B. Ramaswamy
Journal: Annals of Oncology (2019)
A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours
Authors: J. Krauss, T. Eigentler, J. Schreiber, C. Weishaupt, P. Terheyden, L. Heinzerling, P. Mohr, B. Weide, S. Ochsenreither, R. Gutzmer, J.C. Becker, F. Kiecker, F. Funkner, R. Heidenreich, S.-K. Kays, U. Klinkhardt, U.S. Gnad-Vogt, B. Scheel, O. Schönborn-Kellenberger, T. Seibel
Journal: Annals of Oncology (2019)
Peroxisome proliferator-activated receptor ? protects against alcohol-induced liver damage
Authors: Tamie Nakajima, Yuji Kamijo, Naoki Tanaka, Eiko Sugiyama, Eiji Tanaka, Kendo Kiyosawa, Yoshimitsu Fukushima, Jeffrey M Peters, Frank J Gonzalez, Toshifumi Aoyama
Journal: Hepatology (2004)

The mechanisms underlying alcoholic liver disease are not completely understood, but lipid accumulation seems to be central to the cause of this disease. The peroxisome proliferator-activated receptor alpha (PPARalpha) plays an important role in the control of lipid homeostasis, metabolism of bioactive molecules, and modulation of inflammatory responses. To investigate the roles of PPARalpha in alcoholic liver injury, wild-type and PPARalpha-null mice were continuously fed a diet containing 4% ethanol, and liver injury was analyzed. PPARalpha-null mice fed ethanol exhibited marked hepatomegaly, hepatic inflammation, cell toxicity, fibrosis, apoptosis, and mitochondrial swelling. Some of these hepatic abnormalities were consistent with those of patients with alcoholic liver injury and were not found in wild-type mice. Next, the molecular mechanisms of ethanol-induced liver injury in PPARalpha-null mice were investigated, and changes related to ethanol and acetaldehyde metabolism, oxidative stress, inflammation, hepatocyte proliferation, fibrosis, and mitochondrial permeability transition activation occurred specifically in PPARalpha-null mice as compared with wild-type mice. In conclusion, these studies suggest a protective role for PPARalpha in alcoholic liver disease. Humans may be more susceptible to liver toxicity induced by ethanol as PPARalpha expression in human liver is considerably lower compared to that of rodents.
Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: A multicenter study
Authors: M. Alhenc Gelas, F.C. Bidard, P.-E. Heudel, J.-Y. Pierga, L. Cabel, S. Delaloge, J.-S. Frenel, C. Levy, F. Dalenc
Journal: Annals of Oncology (2019)
The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities
Authors: Rami S. Komrokji, Najla H Al Ali, Asmita Mishra, Maria Corrales-Yepez, Eric Padron, Ling Zhang, Pearlie K Epling-Burnette, Bryan J Little, Javier Pinilla-Ibarz, Jeffrey E Lancet, Alan F. List
Journal: Blood (2012)